BioCardia, Inc. (BCDA) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Lose.
25/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 1 wins, 11 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseBCDA / S&P 2.48% / 15.20% |
LoseBCDA / S&P BCDA unavailable / 15.00% |
LoseBCDA / S&P BCDA unavailable / 50.40% |
| 2026-Q11/3 |
WinBCDA / S&P -3.20% / -4.33% |
LoseBCDA / S&P BCDA unavailable / 11.30% |
LoseBCDA / S&P BCDA unavailable / 27.70% |
| 2025-Q40/3 |
LoseBCDA / S&P -3.10% / 2.65% |
LoseBCDA / S&P -100.00% / 9.00% |
LoseBCDA / S&P BCDA unavailable / 13.40% |
| 2025-Q30/3 |
LoseBCDA / S&P -33.85% / 8.12% |
LoseBCDA / S&P -100.00% / 4.61% |
LoseBCDA / S&P BCDA unavailable / 13.45% |
| 2025-Q20/3 |
LoseBCDA / S&P -23.23% / 10.94% |
LoseBCDA / S&P -100.00% / 4.83% |
LoseBCDA / S&P BCDA unavailable / 10.63% |
| 2025-Q11/3 |
WinBCDA / S&P 16.51% / -4.27% |
LoseBCDA / S&P -99.36% / 4.98% |
LoseBCDA / S&P BCDA unavailable / 10.57% |
| 2024-Q40/3 |
LoseBCDA / S&P -30.13% / 2.41% |
LoseBCDA / S&P -87.84% / 5.25% |
LoseBCDA / S&P BCDA unavailable / 6.15% |
| 2024-Q30/3 |
LoseBCDA / S&P 5.05% / 5.89% |
LoseBCDA / S&P -87.54% / 5.89% |
LoseBCDA / S&P BCDA unavailable / 6.11% |
| 2024-Q20/3 |
LoseBCDA / S&P -51.71% / 4.28% |
LoseBCDA / S&P 0.71% / 5.38% |
LoseBCDA / S&P BCDA unavailable / 5.12% |
| 2024-Q10/3 |
LoseBCDA / S&P -37.88% / 10.56% |
LoseBCDA / S&P -65.49% / 5.71% |
LoseBCDA / S&P BCDA unavailable / 5.59% |
| 2023-Q41/3 |
WinBCDA / S&P 53.49% / 11.69% |
LoseBCDA / S&P -64.72% / 6.81% |
LoseBCDA / S&P BCDA unavailable / 7.78% |
| 2023-Q30/3 |
LoseBCDA / S&P -83.90% / -3.27% |
LoseBCDA / S&P -56.98% / 7.52% |
LoseBCDA / S&P BCDA unavailable / -5.03% |
| 2023-Q21/3 |
WinBCDA / S&P 36.92% / 8.74% |
LoseBCDA / S&P -78.02% / 9.50% |
LoseBCDA / S&P BCDA unavailable / -8.57% |
| 2023-Q11/3 |
LoseBCDA / S&P -6.70% / 7.50% |
WinBCDA / S&P 31.78% / 10.77% |
LoseBCDA / S&P BCDA unavailable / -15.69% |
| 2022-Q42/3 |
WinBCDA / S&P 7.73% / 7.56% |
WinBCDA / S&P 33.20% / 11.88% |
LoseBCDA / S&P BCDA unavailable / -17.99% |
| 2022-Q32/3 |
WinBCDA / S&P 33.79% / -4.88% |
WinBCDA / S&P 34.93% / 13.47% |
LoseBCDA / S&P BCDA unavailable / -1.41% |
| 2022-Q21/3 |
LoseBCDA / S&P -29.95% / -16.10% |
WinBCDA / S&P 891.79% / 13.71% |
LoseBCDA / S&P BCDA unavailable / 11.04% |
| 2022-Q12/3 |
WinBCDA / S&P 6.70% / -4.60% |
WinBCDA / S&P 572.55% / 15.97% |
LoseBCDA / S&P BCDA unavailable / 42.23% |
| 2021-Q41/3 |
LoseBCDA / S&P -38.22% / 11.03% |
WinBCDA / S&P 600.00% / 15.00% |
LoseBCDA / S&P BCDA unavailable / 96.40% |
| 2021-Q31/3 |
LoseBCDA / S&P -20.91% / 0.58% |
WinBCDA / S&P 212.74% / 10.77% |
LoseBCDA / S&P BCDA unavailable / 69.42% |
| 2021-Q20/3 |
LoseBCDA / S&P -8.53% / 8.55% |
LoseBCDA / S&P -58.86% / 6.58% |
LoseBCDA / S&P BCDA unavailable / 51.81% |
| 2021-Q11/3 |
WinBCDA / S&P 25.43% / 6.17% |
LoseBCDA / S&P -71.29% / -1.06% |
LoseBCDA / S&P BCDA unavailable / 7.39% |
| 2020-Q41/3 |
WinBCDA / S&P 52.42% / 12.15% |
LoseBCDA / S&P -79.61% / -3.72% |
LoseBCDA / S&P BCDA unavailable / -33.42% |
| 2020-Q30/3 |
LoseBCDA / S&P -5.42% / 8.93% |
LoseBCDA / S&P -47.58% / -2.04% |
LoseBCDA / S&P BCDA unavailable / -27.10% |
| 2020-Q20/3 |
LoseBCDA / S&P -29.20% / 20.54% |
LoseBCDA / S&P -3.07% / -0.46% |
LoseBCDA / S&P BCDA unavailable / -27.11% |
| 2020-Q11/3 |
WinBCDA / S&P -7.88% / -19.60% |
LoseBCDA / S&P -16.98% / 3.47% |
LoseBCDA / S&P BCDA unavailable / -14.75% |
| 2019-Q41/3 |
LoseBCDA / S&P 7.60% / 9.07% |
WinBCDA / S&P 13.76% / 5.36% |
LoseBCDA / S&P BCDA unavailable / 2.99% |
| 2019-Q30/3 |
LoseBCDA / S&P -64.00% / 1.70% |
LoseBCDA / S&P -3.70% / 5.02% |
LoseBCDA / S&P BCDA unavailable / 0.21% |
| 2019-Q20/3 |
LoseBCDA / S&P -21.81% / 4.30% |
LoseBCDA / S&P -26.80% / 6.64% |
LoseBCDA / S&P BCDA unavailable / 8.65% |
| 2019-Q11/3 |
LoseBCDA / S&P 12.50% / 13.65% |
WinBCDA / S&P 18.67% / 8.12% |
LoseBCDA / S&P BCDA unavailable / 14.29% |
| 2018-Q41/3 |
LoseBCDA / S&P -57.60% / -13.52% |
WinBCDA / S&P 30.48% / 9.05% |
LoseBCDA / S&P BCDA unavailable / 18.23% |
| 2018-Q32/3 |
WinBCDA / S&P 106.57% / 7.71% |
WinBCDA / S&P 20.54% / 10.21% |
LoseBCDA / S&P BCDA unavailable / 19.06% |
| 2018-Q21/3 |
LoseBCDA / S&P -27.13% / 3.43% |
WinBCDA / S&P 32.80% / 9.03% |
LoseBCDA / S&P BCDA unavailable / 14.46% |
| 2018-Q10/3 |
LoseBCDA / S&P -20.00% / -0.76% |
LoseBCDA / S&P 1.12% / 7.68% |
LoseBCDA / S&P BCDA unavailable / 12.46% |
| 2017-Q40/3 |
LoseBCDA / S&P -58.33% / 6.64% |
LoseBCDA / S&P -16.84% / 7.03% |
LoseBCDA / S&P BCDA unavailable / 13.82% |
| 2017-Q30/3 |
LoseBCDA / S&P -28.79% / 4.48% |
LoseBCDA / S&P BCDA unavailable / 5.68% |
LoseBCDA / S&P BCDA unavailable / 17.57% |
| 2017-Q21/3 |
WinBCDA / S&P 46.67% / 3.09% |
LoseBCDA / S&P BCDA unavailable / 4.83% |
LoseBCDA / S&P BCDA unavailable / 17.74% |
| 2017-Q10/3 |
LoseBCDA / S&P -58.33% / 6.07% |
LoseBCDA / S&P BCDA unavailable / 3.67% |
LoseBCDA / S&P BCDA unavailable / 13.32% |
| 2016-Q41/3 |
WinBCDA / S&P 800.00% / 3.82% |
LoseBCDA / S&P BCDA unavailable / 2.09% |
LoseBCDA / S&P BCDA unavailable / 7.05% |
| 2016-Q30/3 |
LoseBCDA / S&P -20.00% / 3.85% |
LoseBCDA / S&P BCDA unavailable / 0.20% |
LoseBCDA / S&P BCDA unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | BCDA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -40.91% | 20.78% |
| Annualized return | -40.91% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | BCDA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -97.36% | 83.14% |
| Annualized return | -51.64% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | BCDA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.44% | 319.30% |
| Annualized return | -40.51% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |